Obligations and what you “should” do as a patient living with idiopathic pulmonary fibrosis (IPF) can be all-consuming. I have learned a lot about myself this week after talking to friends and colleagues. One of the things I must let go of throughout this journey is this idea…
‘Should’ vs. ‘Should Not’ as an IPF Patient
Using Esbriet (pirfenidone) or Ofev (nintedanib) for a year reduces lung function decline in idiopathic pulmonary fibrosis (IPF) patients, according to a review of nine clinical trials. Esbriet may also improve patients’ survival. But N-acetylcysteine failed to improve lung function or decrease mortality, the comparative study indicated. The article, “…
When 78-year-old Bill Vicks was diagnosed with pulmonary fibrosis in 2011, doctors gave him three years to live according to an article in capecodtimes.com. The super-fit septuagenarian did what he does best—dons his sneakers and goes out for a run. MORE: How to live for the moment with…
By discovering how the antifibrotic treatments Ofev (nintedanib) and Esbriet (pirfenidone) work, researchers hope to develop even better drugs to treat pulmonary fibrosis. The new insights into these drugs work was gained by making use of a new cell model of lab-grown cells derived from patients. The study,…
When Maureen McDonald’s father passed away from pulmonary fibrosis, she wanted to do something to celebrate his life and raise awareness of the chronic lung disease. She decided to join the annual American Lung Association Greater Chicago Chapter’s “Fight for Air Climb.” MORE: Animated film explains symptoms of pulmonary fibrosis.
I had an experience last night in the emergency room that has left me thinking a lot. So I decided to turn my thoughts into a column — and I am curious to hear how those of you also living with idiopathic pulmonary fibrosis (IPF) feel about patient…
Boehringer Ingelheim has enrolled the first patient with progressive fibrosing interstitial lung disease (PF-ILD) in a clinical trial that will evaluate the safety and effectiveness of Ofev (nintedanib) for treating the condition. The double-blind, randomized, placebo-controlled, Phase 3 clinical trial (NCT02999178) will run for 52 weeks. It will be…
Although most cases of pulmonary fibrosis are not genetic and often unknown when it is called idiopathic pulmonary fibrosis. However, there are rare cases where the condition runs in families suggesting a genetic link to the disease. MORE: The relationship between pulmonary fibrosis and pulmonary hypertension. Researchers have isolated…
Esbriet (pirfenidone) improved life expectancy in patients with idiopathic pulmonary fibrosis (IPF) by approximately 2.5 years compared to best supportive care, according to recent research. The study, “Predicting Life Expectancy For Pirfenidone In Idiopathic Pulmonary Fibrosis,” was published in the Journal of Managed Care Pharmacy. Esbriet has been…
Pulmonary fibrosis is a chronic lung disease where the tissue surrounding the air sacs in the lungs becomes scarred. This scarring, or fibrosis, makes it difficult for the body to get enough oxygen into the bloodstream. The common symptoms of pulmonary fibrosis include shortness of breath, persistent coughing, weight loss and loss…
